巴西某单一中心青少年及青年急性淋巴细胞白血病患者的治疗结果
Outcome of adolescents and young adults with acute lymphoblastic leukemia in a single center in Brazil.
作者信息
Aguiar Thais Ferraz, da Conceição Barbosa Thayana, Maciel Ana Luiza Tardem, Blunck Caroline Barbieri, Sellos-Laclette João, de Melo Andreia Cristina, Mansur Marcela B, Emerenciano Mariana
机构信息
Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil; Instituto Estadual de Hematologia Arthur Siqueira Cavalcanti, Rio de Janeiro, RJ, Brazil.
Instituto Nacional de Câncer (INCA), Rio de Janeiro, RJ, Brazil.
出版信息
Hematol Transfus Cell Ther. 2023 Jul;45 Suppl 2(Suppl 2):S108-S112. doi: 10.1016/j.htct.2022.06.006. Epub 2022 Aug 1.
INTRODUCTION
Acute lymphoblastic leukemia (ALL) presents a poor prognosis in adults. The adoption of pediatric protocols has been changing this scenario, especially for adolescents and young adults (AYA).
OBJECTIVE AND METHOD
We aimed to evaluate a consecutive series of patients treated at the State Institute of Hematology of Rio de Janeiro between 2012 and 2020, focusing on the AYA subgroup.
RESULT
The B-ALL was the most frequent subtype (81.6%) and AYA, the predominant age group (57.7%). The median overall survival (OS) was 9.4 months. High early mortality was observed and sepsis was the main cause of death. Better OS results were noted in AYA, in comparison to over 39y (13.3 × 6.2 months, respectively), the Berlin-Frankfurt-Münster (BFM) being the protocol of choice in this group.
CONCLUSION
The use of the pediatric protocol seems to improve the OS of AYA, however, high rates of deaths from infection were observed, demonstrating the need for advances in the Brazilian public system clinical support.
引言
成人急性淋巴细胞白血病（ALL）的预后较差。采用儿科方案一直在改变这种情况，特别是对于青少年和青年（AYA）。
目的和方法
我们旨在评估2012年至2020年期间在里约热内卢国家血液学研究所接受治疗的一系列连续患者，重点关注AYA亚组。
结果
B-ALL是最常见的亚型（81.6%），AYA是主要年龄组（57.7%）。中位总生存期（OS）为9.4个月。观察到早期死亡率较高，败血症是主要死因。与39岁以上患者相比，AYA的OS结果更好（分别为13.3×6.2个月），柏林-法兰克福-明斯特（BFM）方案是该组的首选方案。
结论
使用儿科方案似乎可改善AYA的OS，然而，观察到感染导致的死亡率较高，这表明巴西公共系统临床支持需要取得进展。
Zotero 插件